Protein spectrum of blood plasma in patients with diabetes mellitus type II

Ионова, В.Г.; Ланцова, В.Б.; Tkach, E A; Ziganshin, Rustam H.; Shender, Victoria О.; Weaver, Eric; Паскова, В.; Antonova, Nadia; Строков, И. А.

doi:10.3233/jcb-179009

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a regulator of innate immunity and was shown to have anticancer activity . The hemoglobin β subunit was found to be downregulated in diabetic patients with complications . Moreover, it was also downregulated in EC tissues when compared to normal tissues and was associated with poor outcomes .…”

Section: Discussionmentioning

confidence: 99%

“…α-1B-glycoprotein is another protein that was found to be downregulated in the ECD patients in our study. Interestingly, it was reported to be overexpressed in the serum of EC patients and downregulated in patients with diabetes and its complications. , It looks like the influence of diabetes has dominated the molecular changes underlying the downregulation of α-1B-glycoprotein. α-1-antichymotrypsin, a glycoprotein and acute-phase protein, is upregulated in EC tissues .…”

Section: Discussionmentioning

confidence: 99%

“… 46 The hemoglobin β subunit was found to be downregulated in diabetic patients with complications. 47 Moreover, it was also downregulated in EC tissues when compared to normal tissues and was associated with poor outcomes. 48 Our study found that the serum abundance of hemoglobin β subunit was significantly lower in patients in the ECD group.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma Proteomic Signature of Endometrial Cancer in Patients with Diabetes

Mujammami,

Rafiullah,

Akkour

et al. 2024

ACS Omega

View full text Add to dashboard Cite

The incidence and mortality of endometrial cancer (EC) have increased in recent years. There is mounting evidence that diabetes may play a role in the greater incidence of EC. The molecular mechanisms of the interaction between type 2 diabetes and EC are not yet clearly understood yet. The present study was undertaken to investigate the plasma proteomics of EC patients with diabetes in comparison to those of EC patients without diabetes. Plasma samples were obtained from age-matched patients (EC diabetic and EC nondiabetic). Untargeted proteomic analysis was carried out using a two-dimensional differential gel electrophoresis coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Of the 33 proteins identified, which significantly differed in the plasma abundance between groups, 17 were upregulated and 16 were downregulated. The majority of the altered proteins are involved in the acute phase reaction, cholesterol metabolism, scavenging of heme from plasma, and plasma lipoprotein assembly and mobilization. α-2-macroglobulin, Ras association domain-containing protein 3, apolipoprotein A-I, α-1B-glycoprotein, and zinc-α-2-glycoprotein were significantly upregulated. The significantly downregulated proteins included haptoglobin, apolipoprotein A-IV, hemopexin, and α-1antichymotrypsin. The differential expression of proteins found in patients who had EC and diabetes indicated severe disease and a poor prognosis. The protein interaction analysis showed dysregulation of cholesterol metabolism and heme scavenging pathways in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Proteomic Signature of Endometrial Cancer in Patients with Diabetes

Mujammami,

Rafiullah,

Akkour

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…This has led to T2DM being the target of many proteomics analyses over the years, trying to uncover patterns of protein expression that lead to insights into the pathogenesis of the disease. Early studies used 2D gel electrophoresis and mass spectrometry (MS) to identify proteins with differential expression in serum or plasma between T2DM and controls (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). These studies identified a wide range of biomarkers, few of which were found consistently across the different studies.…”

Section: Introductionmentioning

confidence: 99%

The remarkable similarity in the serum proteome between type 2 diabetics and controls

Mosedale,

Sharp,

de Graff

et al. 2024

Preprint

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a rapidly increasing threat to global health, which brings with it a demand for better treatments. This study aimed to identify differences in the proteome of patients with T2DM to identify new targets for therapeutic intervention. We used a highly reproducible bottom-up proteomics protocol to investigate differences in protein, peptide and post-translational modifications between subjects with T2DM and matched controls in an untargeted manner. The serum proteome was remarkably similar at the protein level with no differences between the subject groups across 175 proteins and five orders of magnitude. Strong associations were found, however, between fasting serum glucose levels and glycations of abundant serum proteins, including sites on apolipoprotein A1, apolipoprotein A2 and α2- macroglobulin. We also investigated proteome differences associated with BMI, and found all three components of the ternary complex (IGF-binding protein complex acid-labile subunit (ALS), IGF-binding protein 3 (IGFBP-3) and IGF-2) were strongly negatively associated with BMI. The results show the power of a proteomics protocol optimised for precision rather than depth of coverage, which here has identified strong correlations between physiological measurements and very low abundance post-translational modifications. In T2DM any differences in the serum proteome are very small, and likely a consequence rather than a cause of hyperglycaemia.Article highlightsOur goal was to use high-precision label-free bottom-up LC-MS/MS proteomics to investigate differences in the proteome of patients with T2DM and controls, and potentially identify novel targets for future research.The serum proteome is remarkably similar in patients with T2DM and controls, with the only major difference being glycations of abundant serum proteinsAll three components of the ternary complex (comprised of ALS, IGFBP-3 and IGF-2) were strongly negatively associated with BMI.The results highlight the power of a proteomics study designed with three key features at its core: a proteomics protocol optimised for precision rather than depth of coverage; an open bioinformatics approach investigating proteins, peptides and PTMs without prior assumptions about which features are important; and analysis of individual subject samples so that results take into account person-to-person variability

show abstract